Avapritinib reduces cutaneous symptoms and mast cell burden in patients with indolent systemic mastocytosis in the PIONEER study

Karin Hartmann1*, Sigurd Broesby-Olsen2*, Frank Siebenhaar3*, Hanneke O. Elberink4, Jason Gotlib5, Vito Sabato6, Mariana Castells7, Michael W. Deininger8, Mark L. Heaney9, Tracy I. George6, Deepti H. Radia10, Massimo Triggiani11, Paul van Daele12, Daniel J. DeAngelo13, Oleg Schmidt-Kittler14, Hui-Min Lin14, Andrew Morrison14, Brenton Mar14, Cem Akin15**, Marcus Maurer3**

1University of Basel, Basel, Switzerland; 2Odense University Hospital, Odense, Denmark; 3Dermatological Allergology, Allergie-Centrum-Charité-Universitätsmedizin Berlin, Université zu Berlin, and Berlin Institute of Health, Berlin, Germany; 4University Medical Center Groningen, Groningen, The Netherlands; 5Stanford Cancer Institute/Stanford University School of Medicine, Stanford, USA; 6University of Antwerp and Antwerp University Hospital, Antwerp, Belgium; 7Brigham and Women’s Hospital, Boston, USA; 8University of Utah, Salt Lake City, USA; 9Columbia University Medical Center, New York, USA; 10Guy’s & St Thomas’ NHS Foundation Trust, London, UK; 11University of Salerno, Salerno, Italy; 12Erasmus Medical Center, Rotterdam, The Netherlands; 13Dana-Farber Cancer Institute, Boston, USA; 14Blueprint Medicines Corporation, Cambridge, USA; 15University of Michigan, Ann Arbor, USA

6 – 8 June 2020

*,**authors contributed equally
## Disclosures

In relation to this presentation, I declare the following real or perceived conflicts of interest:

<table>
<thead>
<tr>
<th>Type</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Employment full time / part time</td>
<td>University of Basel, Basel, Switzerland</td>
</tr>
<tr>
<td>Consulting, honoraria and reimbursement of travel expenses</td>
<td>ALK-ABelló, Allergopharma, Blueprint Medicines Corporation, Deciphera, Menarini, Novartis and Takeda</td>
</tr>
<tr>
<td>Research Grant</td>
<td>Euroimmun, Thermofisher</td>
</tr>
<tr>
<td>Other research support</td>
<td>None</td>
</tr>
<tr>
<td>Ownership interest (stock, stock-options, patent or intellectual property)</td>
<td>None</td>
</tr>
</tbody>
</table>

AYVAKIT™ (avapritinib) is approved by the FDA for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations, in the United States. Avapritinib has not been approved by the FDA, or any other health authority, for use in the United States for any other indication or in any other jurisdiction for any indication.
Systemic mastocytosis is a clonal mast cell neoplasm driven by \textit{KIT} D816V

- \textit{KIT} D816V mutation drives \textit{mast cell hyperactivation} and \textit{accumulation} throughout various organs\textsuperscript{1}
- This leads to debilitating \textit{skin, gastrointestinal, neurocognitive} and \textit{systemic} symptoms\textsuperscript{2}
- In indolent SM, cutaneous involvement is frequent and is associated with \textit{pruritis, flushing} and \textit{pigmented skin lesions} which can severely impact quality of life\textsuperscript{2}

- Currently \textbf{no approved therapies} effectively reduce the burden of disease in indolent SM, including the skin lesions\textsuperscript{2}

\begin{figure}
\centering
\includegraphics[width=\textwidth]{images}
\caption{Systemic mastocytosis-related skin lesions}
\end{figure}


Patients’ permission granted for use of photos
Avapritinib targets *KIT* D816V with objective and symptomatic responses in SM

Avapritinib is a TKI that is highly potent on *KIT* D816V with a highly selective kinome profile\(^1\)

**Phase I EXPLORER trial:** confirmed ORR of 77% in AdvSM\(^2\)

FDA breakthrough designation for AdvSM

**Phase 2 PATHFINDER in AdvSM enrolling**

**Efficacy on AdvSM symptoms including potential for resolution of mastocytosis in skin\(^2,3\)**

Biochemical IC\(_{50}\) = 0.27 nM\(^1\)

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (CSTI) www.cellsignal.com. The foregoing website is maintained by CSTI and Blueprint Medicines Corporation is not responsible for its content. Previously published in reference 1. Reprinted with permission from AAAS.

Patient permission granted for use of photos.

PIONEER Phase II clinical trial of avapritinib in non-advanced SM

Part 1: dose selection (fully enrolled) – selection of well-tolerated, long-term dose with appropriate benefit–risk for indolent SM

Primary endpoint
Avapritinib 25 mg QD + BSC (n=10)
Avapritinib 50 mg QD + BSC (n=10)
Avapritinib 100 mg QD + BSC (n=10)
Placebo QD + BSC (n=9)

Determination of RP2D
Avapritinib at RP2D + BSC

Rollover
Long term safety and efficacy

Secondary endpoints
- Safety
- Pharmacokinetics
- Changes in mast cell burden*
- Changes in patient-reported outcomes
- Changes in cutaneous disease (photography)
- Changes in skin mast cells (pathology)

RP2D selected as 25 mg QD
Plan to initiate Part 2 patient screening in June 2020

*Measured by reduction of serum tryptase, peripheral blood KIT D816V allele fraction and bone marrow mast cells. BSC, best supportive care; QD, once daily; RP2D, recommended Part 2 dose; SM, systemic mastocytosis.
PIONEER phase II clinical trial of avapritinib in non-advanced SM

Part 2: pivotal efficacy (pending) – registration-enabling portion powered to demonstrate efficacy over placebo

30% or greater reduction in Total Symptom Score (TSS) determined as clinically important response

**Randomize 2:1**

- Avapritinib 25 mg QD + BSC (n=~136)
- Placebo QD + BSC (n=~68)

**Primary endpoint**

- Response at 24 weeks
- 30% or greater reduction in TSS

**Rollover**

- Avapritinib 25 mg QD + BSC
- Long-term safety and efficacy

**Key secondary endpoints**

- Proportions of patients with 50% or greater reduction in:
  - Serum tryptase
  - Peripheral blood KIT D816V allele fraction
  - Bone marrow mast cells
  - Mean change in TSS from Baseline to week 24

**Key eligibility criteria:**

- Age ≥18 years, ECOG performance status 0–2
- Indolent SM confirmed by central pathology review of bone marrow biopsy according to WHO criteria
- Moderate-to-severe symptoms based on minimum mean TSS over the 14-day eligibility screening period despite ≥2 classes of BSC medications
Assessment of avapritinib efficacy on cutaneous signs and symptoms

Patient Reported Outcomes

- Indolent SM-Symptom Assessment Form (ISM-SAF) was completed daily
  - 24-hour recall, analysed as a 14-day average
  - Severity of 11 symptoms ranging from 0 (no symptoms) to 10 (worst imaginable) was asked daily
  - Total Symptom Score (TSS) was the total of all symptoms

Skin Assessments

- High resolution skin photography (front and rear torso and thighs)
  - Percent affected fractional surface area (as determined by best of four detection methods)
  - Most affected region at baseline as determined by the Skin Assessment Committee
  - Colour change over time as determined by the Skin Assessment Committee

- Mast cell number per mm² in lesional skin
## Baseline characteristics of PIONEER population

### Patient demographics

<table>
<thead>
<tr>
<th>Age (years), median (range)</th>
<th>All doses (n=39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>51 (21–75)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sex, n (%), female</th>
<th>All doses (n=39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 (77)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ECOG PS, n (%)</th>
<th>All doses (n=39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>12 (31)</td>
</tr>
<tr>
<td>1</td>
<td>19 (49)</td>
</tr>
<tr>
<td>2</td>
<td>8 (21)</td>
</tr>
</tbody>
</table>

### Mast cell burden

<table>
<thead>
<tr>
<th>Central diagnosis of indolent SM, n (%)</th>
<th>All doses (n=39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>39 (100)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tryptase (central) ng/mL, mean (SD)</th>
<th>All doses (n=39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median (range)</td>
<td></td>
</tr>
<tr>
<td>&lt;11.4 ng/mL, n (%)</td>
<td>45 (6–416)</td>
</tr>
<tr>
<td>11.4 to 20 ng/mL, n (%)</td>
<td>6 (15)</td>
</tr>
<tr>
<td>&gt;20 ng/mL, n (%)</td>
<td>30 (77)</td>
</tr>
</tbody>
</table>

### KIT D816V mutation

<table>
<thead>
<tr>
<th>KIT D816V mutation</th>
<th>Locala</th>
<th>Central NGSb</th>
<th>Central ddPCRc</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (%) detected</td>
<td>31 (80)</td>
<td>11 (28)</td>
<td>37 (95)</td>
</tr>
<tr>
<td>Median MAF, % (range)</td>
<td>11 (1.9–31.6)</td>
<td>0.36 (0.16–30.22)</td>
<td></td>
</tr>
</tbody>
</table>

### SM therapy, n (%)

<table>
<thead>
<tr>
<th>Prior cytoreductive therapy</th>
<th>All doses (n=39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Midostaurin, imatinib, dasatinib</td>
<td>6 (16)</td>
</tr>
<tr>
<td>Interferon-alfa</td>
<td>5 (13)</td>
</tr>
</tbody>
</table>

### Baseline supportive care medications, median (range)

| H1 blockers | 37 (95) |
| H2 blockers | 30 (77) |
| Leukotriene receptor antagonists | 23 (59) |
| Proton pump inhibitors | 18 (46) |
| Cromolyn sodium | 12 (31) |
| Corticosteroids | 6 (15) |
| Omalizumab | 9 (23) |

### Patient disposition

<table>
<thead>
<tr>
<th>Weeks on study median (range)</th>
<th>All doses (n=39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>18 (1–36)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Still on study, n (%)</th>
<th>All doses (n=39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>37 (95)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Discontinued study, n (%)</th>
<th>All doses (n=39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 (5)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient decision, n</th>
<th>All doses (n=39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Protocol non-compliance, n</th>
<th>All doses (n=39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

---

Data in this presentation are based on a cut-off of 27 December 2019 unless otherwise specified.

---

*A local quantitative and qualitative KIT testing of bone marrow and/or blood, various methods and sensitivities. bNGS targeted myeloid panel (central) in blood, algorithmic calling sensitivity to 1.9% MAF. cDigital droplet PCR in blood (central), sensitivity to 0.02% MAF, detected positive at screening or C1D1, Median MAF and range at C1D1 in those with any detection. C1D1, cycle 1 day 1; ECOG PS, Eastern Cooperative Oncology Group performance status; MAF, mutation allele fraction; MC, mast cells; NGS, next generation sequencing; SD, standard deviation; SM, systemic mastocytosis.*

---

Akin et al. AAAAI 2020, Philadelphia, PA
Avapritinib was well tolerated across all doses with no grade 3 AEs at 25 mg

<table>
<thead>
<tr>
<th>Preferred term</th>
<th>Placebo n=9</th>
<th>Avapritinib 25 mg n=10</th>
<th>50 mg n=10</th>
<th>100 mg n=10</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Any grade</td>
<td>Grade 3</td>
<td>Any grade</td>
<td>Grade 3</td>
</tr>
<tr>
<td>Patients with ≥1 AE, %</td>
<td>89</td>
<td>22</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>Nausea</td>
<td>22</td>
<td>0</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Dizziness</td>
<td>22</td>
<td>0</td>
<td>30</td>
<td>0</td>
</tr>
<tr>
<td>Headache</td>
<td>11</td>
<td>0</td>
<td>30</td>
<td>0</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>11</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fatigue</td>
<td>11</td>
<td>0</td>
<td>40</td>
<td>0</td>
</tr>
<tr>
<td>Face oedema</td>
<td>0</td>
<td>0</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Peripheral oedema</td>
<td>0</td>
<td>0</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Periorbital oedema</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Bone pain</td>
<td>22</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

- No Grade 4 or 5 AEs on study
- No patients discontinued treatment due to AEs or progression to AdvSM
- No neutropenia, anaemia, thrombocytopenia or intracranial bleeding
- One Grade 3 cognitive disorder in the 100 mg cohort resolved following dose modification; patient remains on treatment at 25mg

Based on a data cut-off date of 27 December 2019
Avapritinib reduces overall signs and symptoms and mast cell burden in indolent SM

At 25 mg daily, avapritinib induces significant responses in overall symptoms and serum tryptase

Part 2 Primary endpoint
≥30% reduction in ISM-SAF Total Symptom Score at 24 weeks

Response rate: 0%  60%

Part 2 First key secondary endpoint
≥50% tryptase reduction at 24 weeks*

Response rate: 0%  70%

Based on a data cut-off date of 31 March 2020
Avapritinib reduces individual signs and symptoms in indolent SM

At 25 mg daily, avapritinib reduced all individual symptoms, including flushing, spots and itching

Based on a data cut-off date of 31 March 2020
Skin Assessment Committee assessed photography in a blinded fashion

High resolution skin photographs were taken at baseline and every 12 weeks during treatment in patients with significant cutaneous involvement, who consented to photography (n=26)

Most affected region at baseline and color change (a lot lighter to darker) was assessed, examples:

<table>
<thead>
<tr>
<th>A lot lighter</th>
<th>Lighter</th>
<th>No change</th>
<th>Darker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>On study</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patients' permission granted for use of photos
Avapritinib lightens the color of skin lesions

Most affected skin region

- Front thigh, 38%
- Back torso, 19%
- Back thigh, 23%

Data based on Skin Adjudication Meeting on 12 May 2020

*One patient could not be assessed for color change.
Affected surface area determined by image analysis algorithm

- Due to the heterogenous presentation of mastocytosis in skin, four detection methods were developed to determine the affected surface area.

- For each individual patient, the Skin Assessment Committee determined the best detection method at baseline.

- Affected surface area in defined areas of interest was followed every 12 weeks by photography, using the same method for each patient.

*Fractional surface area determined for entire front torso image, but only a portion shown for privacy reasons.
Avapritinib reduces affected surface area of skin lesions

Most affected skin region

Data based on Skin Adjudication Meeting on 12 May 2020
Avapritinib reduces mast cell number in lesional skin biopsies

Baseline

placebo (n=7)

avapritinib (all doses) (n=18)

% change in number of skin MCs per mm² in lesional skin biopsies from Baseline to 12 weeks

4300 MCs/mm²

119 MCs/mm²

CD117

Baseline

12 weeks

MCs, mast cell.
Avapritinib reduces signs, symptoms and mast cell burden in indolent SM

- Clinically meaningful reductions in overall symptoms and serum tryptase at RP2D of 25 mg QD
  - 60% and 70% response rates in TSS and serum tryptase, respectively, versus 0% for placebo

- Avapritinib reduces the signs, symptoms and pathological findings of skin lesions
  - Decreased mean severity of all patient-reported symptoms, including itching, flushing and spots
  - Lightens skin lesions and reduces the affected surface area of lesions in most affected regions
  - Reduces the mast cell numbers in lesional skin biopsies

- Avapritinib has a favorable safety profile in patients with indolent SM, supporting further evaluation of a chronic dosing regimen
  - 95% of patients remain on study, with no discontinuations for AEs
  - No grade ≥3 AEs occurred in the 25 mg QD cohort

Part 2 will be conducted with 25 mg daily and is expected to initiate patient screening in June 2020
# Acknowledgements

## PIONEER part 1 Investigators
- Cem Akin
- Hanneke Oude Elberink
- Jason Gotlib
- Vito Sabato
- Mariana Castells
- Michael W. Deininger
- Mark L. Heaney
- Tracy I. George
- Deepti H. Radia
- Massimo Triggiani
- Paul van Daele
- Daniel J. DeAngelo

## Skin Assessment Committee
- Karin Hartman
- Sigurd Broesby-Olsen
- Frank Siebenhaar
- Marcus Maurer

## Patients and Families
- Karin Hartman
- Sigurd Broesby-Olsen
- Frank Siebenhaar
- Marcus Maurer